ECTRIMS 2022, Amsterdam, the Netherlands and Online

2017
ASCPT 2017, Washington DC, US
Mechanistic model of neutrophil cell dynamics and activation to inform systems pharmacology modeling of the immune response
Authors: Galina Lebedeva, Sergey Smirnov, Evgeny Metelkin, Oleg Demin
Mathematical description of multiple effects of regulatory molecules
Authors: Sergey Smirnov, Evgeny Metelkin, Galina Lebedeva, Oleg Demin
2016
ACoP7, Bellevue, WA, US
Mechanistic approach to describe multiple effects of regulatory molecules on cell dynamics process in immune response
Authors: Oleg Demin, Evgeny Metelkin, Galina Lebedeva, Sergey Smirnov
Quantitative systems pharmacology model of amyloid pathology allows for clinical endpoint prediction and hypothesis testing
Authors: Tatiana Karelina1, Oleg Demin1, Timothy Nicholas2, Sridhar Duvvuri2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
Exploration of differences between mechanism-based PK/PD and systems pharmacology models
Authors: Oleg Demin
Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach
Authors: Oleg Demin Jr
PAGE 2016, Lisboa, Portugal
Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics
Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Elena Shipaeva2, Mikhail Samsonov2, Anna Krotkova2, Yan Lavrovsky3
Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia; 3R-Pharm Overseas, Inc., San Diego, US
The International Liver Congress 2016, Barcelona, Spain
Quantitative Systems Pharmacology model of Hepatitis C: Prediction of Results of Ongoing Clinical Trials of Direct Antiviral Agents Combination Therapies
Authors: Oleg Demin Jr
ASCPT 2016, San Diego, CA, US
Analysis of brain pharmacodynamics of gamma-secretase inhibitors using quantitative translational systems pharmacology model
Authors: Tatiana Karelina1, Oleg Demin1, Timothy Nicholas2, Sridhar Duvvuri2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
Population modeling study for evaluation of effective and safe dose of RPH-104 for the treatment of Behcet’s syndrome and FMF
Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Elena Shipaeva2, Mikhail Samsonov2, Anna Krotkova2, Yan Lavrovsky3
Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia; 3R-Pharm Overseas, Inc., San Diego, US
Systems Pharmacology Model Of Hepatitis C: Exploration Of Effect Of Combinations Of Direct Antiviral Agents On HCV Production During Treatment Of HCV Patients
Authors: Oleg Demin Jr, Oleg Demin
Population modeling and simulation of RPH-203 effects in the context of prevention of skeletal-related events in patients with bone metastases
Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Shorena Archuadze2, Galina Konopleva2, Dmitry Koloda2, Mikhail Samsonov2
Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia
2015
ASCPT 2015, New Orleans, LA, US
Systems Pharmacology Modeling of Hypomethylating agents Decitabine and SGI-110 for Evaluation of AML treatment by targeting the S-phase with prolonged Pharmacokinetic exposures
Authors: Aram Oganesian, Oleg Demin Jr, Antonina Nikitich, Oleg Demin and Mohammad Azab
Affiliation: Astex Pharmaceuticals Inc., Dublin, CA, US; 2InSysBio, Moscow, Russia